Ra Capital Management, L.P. Purchases 9,906 Shares of Hemab Therapeutics (NASDAQ:COAG) Stock

Posted by Wayne Rhoads on May 13th, 2026

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) major shareholder Ra Capital Management, L.P. purchased 9,906 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were bought at an average price of $24.46 per share, for a total transaction of $242,300.76. Following the completion of the transaction, the insider owned 6,324,431 shares of the company’s stock, valued at approximately $154,695,582.26. This trade represents a 0.16% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

On Monday, May 11th, Ra Capital Management, L.P. purchased 39,869 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.81 per share, for a total transaction of $989,149.89.
On Friday, May 8th, Ra Capital Management, L.P. purchased 1,483 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.98 per share, for a total transaction of $37,045.34.
On Wednesday, May 6th, Ra Capital Management, L.P. purchased 68,018 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.60 per share, for a total transaction of $1,673,242.80.
On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.63 per share, for a total transaction of $2,399,232.93.
On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The shares were bought at an average price of $18.00 per share, for a total transaction of $48,150,000.00.